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Background: Angiotensin receptor neprilysin inhibitor (ARNI) sacubitril-valsartan has
been recommended as one of the first-line therapies in heart failure with reduced
ejection fraction. However, whether ARNI could benefit patients with ST-segment
elevation myocardial infarction (STEMI) by improving left ventricular (LV) remodeling
remains unknown. The primary objective of the PERI-STEMI trial is to assess whether
sacubitril-valsartan is more effective in preventing adverse LV remodeling for
patients with STEMI than enalapril.
Hypothesis: We hypothesize that sacubitril/valsartan is superior to enalapril in
preventing adverse LV remodeling evaluated by cardiovascular magnetic resonance
imaging at the 6-month follow-up.
Methods: PERI-STEMI is an investigator-initiated, prospective, multi-center, random-
ized, open-label, superiority trial with blinded evaluation of outcomes. A total of
376 first-time STEMI patients with primary percutaneous coronary intervention
(PPCI) within 12 h after symptom onset will be randomized to sacubitril-valsartan or
enalapril treatment. All the patients will receive a baseline cardiovascular magnetic
resonance (CMR) examination at 4–7 days post-PPCI. The primary endpoint is the
change of indexed LV mass at the 6-month follow-up CMR.
Results: Enrollment of the first patient is planned in November 2021. Recruitment is
anticipated to last for 12–18 months and patients will be followed for 5 years after
randomization. The study is expected to complete in June 2027.
Jiayu Sun and Yong He co-supervise the work.
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Conclusions: The results of the PERI-STEMI trial are expected to provide CMR evi-
dence on whether ARNI could benefit patients with STEMI, so as to facilitate the
strategy of CMR-based risk stratification and therapy selection for these patients.
PERI-STEMI is registered at ClinicalTrials.gov (NCT04912167).
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1 | BACKGROUND
Angiotensin receptor neprilysin inhibitor (ARNI) sacubitril-valsartan, also
known as LCZ696, has proven its superiority over enalapril in reducing
adverse clinical events in patients with heart failure (HF) and reduced
ejection fraction (HFrEF).1 Further study showed that treatment with
sacubitril-valsartan compared to valsartan alone is associated with sig-
nificant improvement in cardiac function and reverse remodeling.2,3
Although these benefits for HF with preserved ejection fraction
(HFpEF) was not significant, a number of studies have reported that use
of sacubitril-valsartan could result in a lower level of N-terminal pro-B-
type natriuretic peptide (NT-proBNP) and an improvement in left atrial
function.4–6 Given that HF represents a heterogenous group of patients,
and a differential treatment effect in this broad population raised by pre-
vious data, studies on specific subtype of patients with HFrEF or HFpEF
are warranted to recognize the target patients who might benefit most
from sacubitril-valsartan treatment.5
Ischemia heart disease (IHD), especially a history of myocardial
infarction (MI), is a common etiology of HF.7,8 Such patients harbor a
high risk of recurrent cardiovascular events and poor prognosis.9,10
Early presence and pattern of left ventricular (LV) remodeling were
closely associated with the long-term outcome and should be carefully
evaluated.11–13 Angiotensin-converting enzyme inhibitors (ACEI) or
angiotensin receptor blocker (ARB) are thus suggested for consider-
ation in all MI patients, owing to their additional benefits and
protecting mechanism on the heart and vasculature remodeling.14–16
Sacubitril-valsartan is efficacious in preventing maladaptive cardiac
fibrosis and prevent adverse LV remodeling compared to ACEI treat-
ment.17 This superiority has been proven in hypertension, acute HF
and MI animal models.18,19 Nevertheless, whether it is effective in
preventing adverse remodeling, or improving reverse remodeling
among patients with ST-segment elevation MI (STEMI) remains
unknown.
Thus, we present the PERI-STEMI (Prospective comparison of
Early Remodeling Imaging between ARNI sacubitril/valsartan and
ACEI enalapril in ST-elevation myocardial infarction patients) trial. The
primary objective of this study is to decide whether sacubitril-
valsartan is more effective in preventing adverse LV remodeling for
patients with STEMI, compared to enalapril. We hypothesize that
sacubitril/valsartan is superior to enalapril in preventing adverse LV
remodeling evaluated by cardiovascular magnetic resonance (CMR)
imaging at the 6-month follow-up. Secondary objectives include:
(a) To examine the long-term outcome of sacubitril-valsartan in
STEMI, as compared to enalapril; and (b) to explore the capacity of
baseline CMR markers in predicting patients who might benefit from
treatment of sacubitril–valsartan.
2 | METHODS
2.1 | Study design
This study is an investigator-initiated, multi-center, open-label,
parallel-group, superiority study (Figure 1). Patients will be recruited
from approximately 20 hospitals in China. This study has been
approved by the ethic committee of West China hospital and all par-
ticipating centers. PERI-STEMI is registered at ClinicalTrials.gov
(NCT04912167).
2.2 | Patient eligibility
Detailed inclusion and exclusion criteria are presented in Table 1.
Briefly, continuous patients aged between 18 and 75 and referred to
the designated chest pain center with the diagnosis of spontaneous
STEMI will be initially screened. The diagnosis of STEMI will be
decided by the physician based on the newest clinical guidelines.14,20
Considering that multiple factors may affect ventricular remodeling,
this study will only include patients with a uniform baseline condition,
namely first-onset STEMI, successfully treated by primary percutane-
ous coronary intervention (PPCI) within 12 h after onset, and hemo-
dynamically stable to be eligible for further evaluation.
Hemodynamically stable is defined as fulfilling the following criteria:
(a) systolic blood pressure (SBP) ≥ 100 mmHg for patients who
received ACEI/ARB during the last 24 h or SBP ≥110 mmHg for
patients who did not, (b) no increase intravenous treatment with
diuretics or vasodilators, and (c) no vasopressors and/or inotropes
during the last 24 h prior to randomization.21
2.3 | Randomization and binding procedure
No run-in period is included for PERI-STEMI. Following screening
patients who fulfill the eligibility criteria will be randomized (1:1) to
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either sacubitril–valsartan or enalapril. Permuted block randomization
stratified by center will be employed. Randomization will be per-
formed through an Interactive Web-based Response System, for
which a random allocation sequence is created using a standard com-
puterized random-number generator. This study is an open-label trial,
but the radiologists responsible for imaging analysis will be rigorously
blind to the clinical and allocation information.
2.4 | Treatment protocol
Standard peri-PPCI clinical management will be applied for each par-
ticipant. The prescriptions of anticoagulants, glycoprotein IIb/IIIa
inhibitors, and thrombus aspiration will be left to the physician's dis-
cretion. For the patients with multivessel disease (MVD), revasculari-
zation of the non-ischemia related artery is suggested but whether to
perform this immediately or in a staged way will be left to the physi-
cian's discretion. Subsequently, patients randomized to ARNI group
will receive two doses of ARB to ensure a minimum 36-h washout
period prior to initiation of ARNI therapy, and then be started with
the first dose or sacubitril-valsartan, while patients randomized to
ACEI group will directly start with the first dose of enalapril. All
patients will be monitored for hypotension 6 h after study treatment.
In accordance with the current clinical management guidelines, all
patients will receive a dual-antiplatelet drug (aspirin, clopidogrel, or
ticagrelor), β-blocker agent and statins as the standard of post-STEMI
care. The use of sodium-dependent glucose cotransporter 2 inhibitor
(SGLT-2i) for patients with diabetes will be left to the physician's dis-
cretion and recorded.
After initiation of treatment with sacubitril-valsartan or enalapril,
dose of the treatment will be titrated to a target level based on sys-
tolic blood pressure of the patients (Table 2). Clinicians are encour-
aged to uptitrate sacubitril-valsartan and enalapril to target dose.
2.5 | Imaging study and analysis
Image acquisition will be performed twice by qualified cardiac MRI
experts with over 5 years working experience of cardiac MR imaging.
The participating centers need to be equipped with MRI scan on 1.5 T
or 3.0 T platforms with dedicated cardiac receiver coils. During imag-
ing, the patients will be kept in supine position. A standard electrocar-
diographic triggering device will be used for heart rate triggering and
monitoring.
A sample protocol is provided for all modalities (Figure 2). The
participating sites will be allowed to use their own acquisition
F IGURE 1 Study plan. ACEI,
angiotensin-converting enzyme inhibitors;
ARNI, angiotensin receptor neprilysin
inhibitor; ECG, electrocardiogram; MACE,
major adverse, cardiac event; MRI,
magnetic resonance imaging; STEMI,
ST-segment elevation myocardial
infarction
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protocols, provided that standard cine, late gadolinium enhancement
(LGE) and mapping images should be acquired according to the cur-
rent practice guidelines. In the sample protocol, a balanced steady
state free precession sequence (bSSFP) will be used to acquire contin-
uous short-axis (SAX) slices encompassing the whole LV, standard
two-, three-, and four-chamber cine images during repeated breath
holds. After then, a dose of 0.1 mmol/kg Gadolinium will be injected
at a flow rate of 2.5–3.0 ml/s. LGE images will be acquired 10–15 min
after contrast administration using a phase-sensitive inversion recov-
ery sequence. Pre-contrast T1 mapping and T2 mapping will be
acquired, and a repeat MOLLI T1 mapping will be performed after
LGE for the post-T1 mapping.
All the image data will be sent to a core-laboratory located at a
dedicated high-volume and experienced hospital for analysis. Two
analysts with at least 5 years working experience in CMR analysis will
perform the image analysis independently and blindly to the clinical
data or treatment allocation information. Any discrepancy between
the two radiologists will be referred to a superior radiologist and car-
diologist to adjudicate.
2.6 | Baseline and follow-up examinations
All patients will be followed for a period of 5 years after PCI (including
an in-patient visit at 6 months, one required out-patient visit at
30 days and 1 year, and seven another out-patient or telephone
visits). Echocardiography, electrocardiogram, 6-min walk test and lab-
oratory examinations will be taken at baseline, 6-month in-patient
visit, and 1-year out-patient visit. CMR examinations and life quality
evaluations using the Kansas City Cardiomyopathy Questionnaire
(KCCQ-12) will be performed at the acute phase (4–7 days after PCI)
and chronic phase (6 months after PCI) respectively. For each visit,
patients will be assessed for major adverse cardiac events (MACE) and
any medical treatments will be recorded (details in Supporting
information A).
2.7 | Clinical data collection and monitoring
All study data will be recorded in a secure electronic data capture sys-
tem (EDC) designed based on a case record form (CRF) that enables
logging of all data entries. For each patient, only the subject number
and initials will be recorded in the CRFs. The demographic data, labo-
ratory examination results, PCI procedure records, ECG and echocar-
diography records will be obtained for each patient by a trained
clinical research coordinator. The coordinator will maintain a personal
subject identification list to make sure that all records are identified.
All investigators will have access to the EDC. The study is monitored
by an independent Data and Safety Monitoring Board (DSMB), which
will be monitoring the safety of the participants and the interim effi-
cacy analysis. Additionally, an independent Central Endpoint Commit-
tee (CEC) will be set up to adjudicate the deaths and important clinical
outcomes. The CEC will be rigorously blinded to group allocation of
the patients. (Details in Supporting information B).
2.8 | Endpoints definition
The main endpoint is selected to characterize the effect of ARNI on
ventricular remodeling as compared to ACEI. Based on the results
TABLE 1 List of inclusion and exclusion criteria for patients
List of inclusion and exclusion criteria for patients
Inclusion criteria
Aged between 18 and 75 years old
First-time ST-segment elevation myocardial infarction based on the
newest ESC guidelinesa
Timely primary percutaneous coronary intervention within 12 h
from onsetb
Written informed consent acquired
Exclusion criteria
Patients with symptomatic hypotension, or a systematic blood
pressure less than 100 mm Hg at screening or 95 mm Hg at
randomization.
Patients with Takotsubo cardiomyopathy or myocardial infarction
secondary to another medical condition such as anemia,
hypotension, or arrhythmia, coronary vasospasm
Known history of or persistent clinical chronic heart failure prior to
randomization
Previous use of ARNI, or intolerance or contraindications to study
drugs including ARNI or ACEI
History of significant chronic coronary obstruction and adverse
ventricular remodeling
History of any cardiomyopathy, valvular heart disease, congenital
heart disease, stent or CABG, or planned open-heart surgery
within 3 months
History of hepatic impairment or history of cirrhosis with evidence
of portal hypertension
History of chronic renal dysfunction, or eGFR <30 ml/min/1.73 m2
History of malignancy and with a life span less than 1 year
Patients with a known history of angioedema related to previous
ACEIs/ARB therapy.
With contraindication to MRI examination (pacemaker and
claustrophobia) or cannot finish breath-holding when lying on the
examination bed
Pregnancy or nursing women
Abbreviations: ACEI, angiotensin-converting enzyme; ARB, angiotensin-
receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; CABG,
coronary artery bypass graft; eGFR, estimated glomerular filtration rate;
ESC, European Society of Cardiology; MRI, magnetic resonance imaging.
aIncluding: (a) evidence of myocardial injury (defined as an elevation of
cardiac troponin values with at least one value above the 99th percentile
upper reference limit) with necrosis in a clinical setting consistent with
myocardial ischemia; and (b) ST-segment elevation in at least two
contiguous leads.
bThe definition of successful revascularization requires (a) a minimum
stenosis diameter reduction to 20% for the culprit vessel; (b) a grade 3
TIMI flow assessed by angiography.
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from previous studies on LV remodeling, change of the indexed LV
mass (Δ LVmassi) from baseline to 6-month follow-up on CMR is set
to be the measurement for the primary outcome.22
Similarly, other secondary CMR outcomes include other remo-
deling parameters from baseline to 6-month follow-up (Δ left ventric-
ular ejection fraction [LVEF], Δ LVEDV, Δ LVESV), peak LV strains
(global radial peak strain, global circumferential peak strain, and global
longitudinal peak strain), strain rates (global radial peak strain rate,
global circumferential peak strain rate, and global longitudinal peak
strain rate), infarction size as measured through LGE, presence of
microvascular obstruction (MVO) on LGE, presence of iron load evalu-
ated on T2* images, T1 mapping, and T2 mapping indexes at the
6-month CMR.
2.9 | The long-term effects of ARNI on LV
remodeling and clinical outcomes in patients will also
be assessed in our study
Thus, key laboratory biomarkers are examined through both arms
from baseline to 5-year follow-up: (a) HF related laboratory markers
(NT-proBNP, soluble growth stimulating express gene 2 (sST2);
(b) myocardium injury related laboratory markers (cardiac troponin T,
interleukin [IL]-1, IL-6, etc.); (c) MACE, including all deaths (cardiac
death vs. non-cardiac death23), non-fatal myocardial re-infarction,24
hospitalization for worsening heart failure or need for advanced HF
therapies (hospital stay >24 h)25 (e.g., intravenous use of inotropes,
LV assist device placement, or cardiac transplantation) (details in
Supporting information C).
The safety assessments for this study include adverse events as
follows: incidence of angioedema, symptomatic hypotension, renal
insufficiency (i.e., assessed by serum creatinine, estimated glomerular
filtration rate [eGFR] and presence of proteinuria, hematuria, and gly-
cosuria), and hyperkalemia. The incidence of the above adverse events
will be reported (Supporting information D).
No prespecified sub-studies are planned in this study.
2.10 | Sample size calculation
The sample size is estimated based on the primary endpoint measure-
ment, that is, Δ LVmassi. Based on the review of published studies
TABLE 2 Target treatment dose levels based on systolic blood pressure
Dose level Sacubitril-valsartan Enalapril Systolic blood pressure (SBP)
1 24/26 mg bid 2.5 mg bid Initial SBP within 100–120 mm Hg and reducing to
<100 mg Hg post-treatment
2 49/51 mg bid 5 mg bid Initial SBP within 100–120 mm Hg and maintaining
≥110 mm Hg post-treatment, or Initial SBP
≥120 mm Hg but reducing to <100 mg Hg post-
treatment
3 97/103 mg bid 10 mg bid Initial SBP ≥120 mm Hg and maintaining ≥110 mm Hg
post-treatment
Note: Bid: twice a day.
F IGURE 2 Cardiovascular magnetic
resonance imaging protocol. 2ch, two
chamber, 3ch, three chamber, 4ch, four
chamber, LV, left ventricle, RV, right
ventricle
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and a meta-analysis summarizing the reported LV remodeling indexes
between ARNI group and ACEI group, an average of approximately
4.81 g/m2 should be expected for the difference in Δ LVmassi at
6 months from baseline between the ARNI group and ACEI group,
with an SD to be 16.65 g/m2.12 A sample size of 188 patients for each
group (i.e., a total of 376 patients) was chosen to achieve ≥80% power
for testing superiority of the ARNI group. Considering a maximum of
15% loss to follow-up (based on the reported follow-up rate at 4.3%–
20%), a target sample size of 442 patients are planned to be initially
recruited.26,27
2.11 | Statistical analysis
Primary trial analyses will be based on the modified intention to treat
(ITT) population in which patients without a measurement of primary
outcome will be excluded and additional analyses will also be per-
formed on the per protocol population (PP). Considering that patients
who received implantation of implantable cardioverter defibrillator
(ICD) or cardiac resynchronization therapy (CRT) within 6 months will
be unable to receive the second MRI examination, ITT population will
consist of all randomized patients with valid outcome measurement.
PP population is a subset of the ITT population in which patients with
major protocol deviations will be excluded. Protocol deviations will be
defined in the statistical analysis plan.
For the analysis of the primary outcome (change of the indexed
LV mass (Δ LVmassi) from baseline to 6-month follow-up on CMR), a
linear regression model will be employed with treatment as the study
variable and baseline measurement of indexed LV mass as a covariate.
In addition, adjusted linear model analysis will be performed with the
pre-specified covariates (LVEF, anterior infarction, MVD, presence of
MVO on LGE, diabetes, hypertension, and the use of SGLT2i) mea-
sured at baseline being added into the above linear model. The crude
and adjusted mean differences in the primary outcome together with
its 95% confidence intervals at 6-months will be derived from the lin-
ear models. In addition, subgroup analysis of primary endpoint will be
performed on the above pre-specified covariates.
Analysis of secondary continuous outcomes with single follow-up
measurement will be done in a similar fashion as the primary endpoint
analysis. Analysis of secondary continuous outcomes with repeated
follow-up measurement will be performed using a linear mixed model
with treatment visit, interaction between treatment and visit as fixed
effects, the baseline value of the outcome as covariate if it is available,
and subject as random effects. The analysis of binary outcomes will also
use a generalized linear/mixed model depending on whether there will
be a repeated measurement. Odds ratios with their 95% confidence
intervals will be derived from the generalized linear/mixed model analy-
sis. For the analysis of time-to-event outcome, Kaplan–Meier curves will
be presented and compared by log rank test by treatment group, and
hazard ratio and its 95% CI will be calculated using Cox regression
model with the treatment arm as the study variable.
Missing primary outcome and secondary outcomes with a single
measurement will not be imputed but missing secondary outcomes
with repeated measurements will be imputed in sensitivity analysis
using the last observation carried forward strategy. Missing baseline
covariates will be imputed using simple imputation methods in the
covariate adjusted analysis based on the covariate distributions in the
sample. For a continuous variable, missing values will be imputed from
random values from a normal distribution with mean and SD calcu-
lated from the available sample. For a categorical variable, missing
values will be imputed from random values from a uniform distribu-
tion with probabilities P1, P2,…, and Pk from the sample. Seed for the
imputation is set as the date of data analysis (e.g., 270 521).
The study is powered to make a single comparison in the primary
outcome at 6 months only and other comparisons are exploratory in
nature. Therefore, there is no multiplicity issue. All analyses will be
described in detail in the statistical analysis plan. SAS 9.4 will be
employed for the statistical analyses.
3 | RESULTS
The study is estimated to be started in November 2021. Recruitment
is supposed to be finished by the end of 2022. Primary results of the
trial are anticipated in June 2023. The planned end date for the trial is
June 2027.
4 | DISCUSSION
The major purpose of PERI-STEMI trial is to decide whether ARNI
could bring superior cardiovascular benefit for patients with STEMI,
when it is compared to traditional ACEI treatment. Additionally,
through meticulous morphology, function and tissue characterization
analysis on CMR, we also aimed to investigate the mechanism of
ARNI in improving reverse remodeling, as well as seek CMR indexes
for predicting maximum benefit from ARNI among such patients.
Potentially, we could provide imaging evidence on application of ARNI
in STEMI, and help elucidate the cardiovascular protection mechanism
of this medicine.
The most innovative design of this trial is utilization of CMR for
the evaluation of ventricular remodeling, cardiac function improve-
ment, and other changes in the comparison between the patients. The
promising cardiovascular effects of ARNI for patients with high LV
load or who are prone to heart failure have been proven in previous
studies. Several animal studies also produce positive evidence on
implementation of ARNI in MI.3,28 A recent study by Rezq et al dem-
onstrated that compared to ACEI, ARNI is superior in preventing early
(at 30 days) adverse clinical events and improving reverse remodeling
for patients with STEMI by using echocardiography.29 Furthermore, a
recent meta-analysis on LV remodeling studies comparing ARNI ver-
sus ACEI/ARB in a heterogenous group of patients reported a distinct
improved LV size and hypertrophy for patients prescribed with ARNI,
even after short-term follow-up (shortest at 3 months in patients with
essential hypertension).22 Especially, LVmassi presents significant dif-
ference in patients with both reduced and preserved LVEF.
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Nevertheless, CMR study in this scenario is rare. Considering that
CMR is recommended as gold standard in cardiac function measure-
ments, our trial sets the CMR-derived 6-month remodeling indexes as
the primary outcome measurement.30,31
Apart from accurate morphological and functional assessment,
CMR's incremental prognostic value in predicting long-term mortality
and non-vital cardiovascular events was also recognized, due to its
unique capacity to observe and quantify myocardial fibrosis progres-
sion, edema and other tissue characterization change through LGE
and mapping sequence.32,33 Myocardial stunning is quite commonly
seen in patients with STEMI and CMR, especially, and has unique abil-
ity to assess myocardial viability by providing accurate quantification
of scar burden and myocardium perfusion.34,35 Whether ARNI could
provide cardiovascular benefits through improving myocardial viability
and whether ARNI has a different role in patients with and without
myocardium stunning warrant further investigation. A recent study
suggested use of CMR for further risk stratification on STEMI patients
with lower LVEF on echocardiography.36 Thus, with a multiple-
sequence design in our CMR protocol for this trial, we proposed that
PERI-STEMI could better demonstrate the advanced functional bene-
fits ARNI could bring, as well as pave understanding of its cardiovas-
cular mechanism.
Beyond comparing the function on early ventricular remodeling
between ARNI and ACEI, another major clinical implication of this
study will be that whether ARNI could bring long-term benefits for
patients with STEMI. Another published trial on the use of ARNI in
acute MI, namely PARADISE-MI trial, only included patients with an
LVEF ≤40%. And their newly reported results indicated numerical but
not statistical difference between ARNI group and ACEI group regard-
ing the pre-specified primary outcome (https://accscientificsession.
acc.org). In addition, the results from PARADISE-MI trial indicated that
long-term use of ARNI might help improve the outcome. Thus, more
evidence is warranted in this field. However, LVEF is only a crude esti-
mate of LV function.37 It is not sensitive to myocardial injury, or an
ideal predictor for developing adverse LV remodeling.38,39 A certain
number of patients with normal LVEF developed adverse clinical out-
comes while some patients with reduced LVEF at acute phase
improved in the long-term follow-up.40,41 Vaduganathan et al's study
provided evidence that an LVEF of 40%–55% might also benefit from
several HF treatments, suggesting a potential benefit of ARNI in part
of the patients with preserved LVEF, especially for STEMI who are
already at high risk of poor prognosis.42,43 Thus, it might be inappro-
priate to arbitrarily only include patients with reduced LVEF when
assessing the efficacy of ARNI in STEMI. Considering that no standard
cut-off for other CMR indexes has been set up to decide the patients
at stake, our trial is designed not to exclude patients only based on
imaging markers immediately after PPCI. Hopefully, this could contrib-
ute by answering the question whether additional CMR indexes could
be used for further risk stratification of the patients with STEMI.
Another merit of this trial is that we rigorously include patients
with timely revascularization, and who are hemodynamically stable.
Considering the potential effects PPCI procedure might have on the
baseline myocardium characterization of the patients, inclusion
criteria is enriched to avoid the bias from procedure or the baseline
condition of the patients. In addition, for these patients, possibility of
having a CRT is relatively low, and thus a later exclusion could be
prevented.
4.1 | Limitations
As with any other clinical trial, our study has several limitations that
should be mentioned. First, only hemodynamic stable patients who
receive successful revascularization within 12 h, and who do not
receive CRT or ICD implantation within 6 months will be finally
included, thus certain bias exists and the interpretation of our results
should be careful. Second, there might be a regional variation in the
clinical outcomes in this multi-center study. The study is powered to
assess the difference in the change of the indexed LV mass
(Δ LVmassi) from baseline to 6-month follow-up on CMR, which is a
surrogate endpoint. We expect to collect some data on clinical out-
comes from this study to plan a future large randomized clinical trial
to assess the clinical efficacy of ARNI. Third, the major index observed
in this study is an imaging marker, which will be measured objectively
through an independent and blinded Core Laboratory. However, bias
might still exist because the patients are not blinded. Nevertheless, LV
remodeling is a relatively objective change and has not been reported
related to the patient's subjective feeling. Measurements of primary
and secondary outcomes including both imaging reading and clinical
events assessment, data management and development of statistical
analysis plan will be kept rigorously blinded to avoid potential bias.
Finally, as this is an MRI study and intended to compare the effects of
ARNI versus ACEI on LV remodeling, the results of the study will need
to be carefully interpreted when transferring to clinical application.
Although clinical outcomes will also be assessed in our study, those
analyses will be exploratory in nature as the study is not powered to
assess the effects of ARNI on clinical outcomes.
5 | CONCLUSION
Patients with STEMI are prone to heart failure and adverse ventricular
remodeling is a risk factor at early follow-up. The PERI-STEMI trial will
be the first CMR study to test the effects of ARNI in patients with
STEMI. Results of this trial will provide evidence on implementation
of ARNI therapy in STEMI, and help elucidate the cardiovascular pro-
tection mechanism of ARNI.
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